FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias.

Date publication

octobre 2022

Journal

European urology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ROCHEL-GUIBERTEAU Natacha

Tous les auteurs :
Shi MJ, Fontugne J, Moreno-Vega A, Meng XY, Groeneveld C, Dufour F, Kamoun A, Viborg Lindskrog S, Cabel L, Krucker C, Rapinat A, Dunois-Larde C, Lepage ML, Chapeaublanc E, Levrel O, Dixon V, Lebret T, Almeida A, De Reynies A, Rochel N, Dyrskjøt L, Allory Y, Radvanyi F, Bernard-Pierrot I

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36273937

Résumé

Bladder cancer (BCa) is more common in men and presents differences in molecular subtypes based on sex. Fibroblast growth factor receptor 3 (FGFR3) mutations are enriched in the luminal papillary muscle-invasive BCa (MIBC) and non-MIBC subtypes.

Mots clés

Androgen receptor, Bladder cancer, Estrogen receptor, Fibroblast growth factor receptor 3, Luminal tumors, Mouse model, Sex bias, Tumor microenvironment, Tyrosine kinase receptor

Référence

Eur Urol. 2022 10 20;: